Literature DB >> 19371602

Paraoxonase 1 (PON1) modulates the toxicity of mixed organophosphorus compounds.

Karen L Jansen1, Toby B Cole, Sarah S Park, Clement E Furlong, Lucio G Costa.   

Abstract

A transgenic mouse model of the human hPON1(Q192R) polymorphism was used to address the role of paraoxonase (PON1) in modulating toxicity associated with exposure to mixtures of organophosphorus (OP) compounds. Chlorpyrifos oxon (CPO), diazoxon (DZO), and paraoxon (PO) are potent inhibitors of carboxylesterases (CaE). We hypothesized that a prior exposure to these OPs would increase sensitivity to malaoxon (MO), a CaE substrate, and the degree of the effect would vary among PON1 genotypes if the OP was a physiologically significant PON1 substrate in vivo. CPO and DZO are detoxified by PON1. For CPO hydrolysis, hPON1(R192) has a higher catalytic efficiency than hPON1(Q192). For DZO hydrolysis, the two alloforms have nearly equal catalytic efficiencies. For PO hydrolysis, the catalytic efficiency of PON1 is too low to be physiologically relevant. When wild-type mice were exposed dermally to CPO, DZO, or PO followed 4-h later by increasing doses of MO, toxicity was increased compared to mice receiving MO alone, presumably due to CaE inhibition. Potentiation of MO toxicity by CPO and DZO was greater in PON1(-/-) mice, which have greatly reduced capacity to detoxify CPO or DZO. Potentiation by CPO was more pronounced in hPON1(Q192) mice than in hPON1(R192) mice due to the decreased efficiency of hPON1(Q192) for detoxifying CPO. Potentiation by DZO was similar in hPON1(Q192) and hPON1(R192) mice, which are equally efficient at hydrolyzing DZO. Potentiation by PO was equivalent among all four genotypes. These results indicate that PON1 status can have a major influence on CaE-mediated detoxication of OP compounds.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19371602      PMCID: PMC2717945          DOI: 10.1016/j.taap.2009.02.001

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  57 in total

1.  Potentiation and neurotoxicity induced by certain organophosphates.

Authors:  J E CASIDA; R L BARON; M ETO; J L ENGEL
Journal:  Biochem Pharmacol       Date:  1963-01       Impact factor: 5.858

2.  Purification of two rat hepatic proteins with A-esterase activity toward chlorpyrifos-oxon and paraoxon.

Authors:  A L Pond; H W Chambers; C P Coyne; J E Chambers
Journal:  J Pharmacol Exp Ther       Date:  1998-09       Impact factor: 4.030

3.  Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma.

Authors:  Bin Li; Meghan Sedlacek; Indumathi Manoharan; Rathnam Boopathy; Ellen G Duysen; Patrick Masson; Oksana Lockridge
Journal:  Biochem Pharmacol       Date:  2005-10-06       Impact factor: 5.858

4.  Malathion A and B esterases of mouse liver--III: In vivo effect of parathion and related PNP-containing insecticides on esterase inhibition and potentiation of malathion toxicity.

Authors:  N Ramakrishna; B V Ramachandran
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

Review 5.  Current issues in organophosphate toxicology.

Authors:  Lucio G Costa
Journal:  Clin Chim Acta       Date:  2005-12-06       Impact factor: 3.786

6.  Detoxication of paraoxon by rat liver homogenate and serum carboxylesterases and A-esterases.

Authors:  J Tang; J E Chambers
Journal:  J Biochem Mol Toxicol       Date:  1999       Impact factor: 3.642

7.  Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes.

Authors:  J Tang; Y Cao; R L Rose; A A Brimfield; D Dai; J A Goldstein; E Hodgson
Journal:  Drug Metab Dispos       Date:  2001-09       Impact factor: 3.922

8.  Identification of rat and human cytochrome p450 isoforms and a rat serum esterase that metabolize the pyrethroid insecticides deltamethrin and esfenvalerate.

Authors:  Stephen J Godin; J Allen Crow; Edward J Scollon; Michael F Hughes; Michael J DeVito; Matthew K Ross
Journal:  Drug Metab Dispos       Date:  2007-06-18       Impact factor: 3.922

9.  Paraoxonase 1 (PON1) status and substrate hydrolysis.

Authors:  Rebecca J Richter; Gail P Jarvik; Clement E Furlong
Journal:  Toxicol Appl Pharmacol       Date:  2008-11-13       Impact factor: 4.219

10.  Expression of human paraoxonase (PON1) during development.

Authors:  Toby B Cole; Rachel L Jampsa; Betsy J Walter; Tara L Arndt; Rebecca J Richter; Diana M Shih; Aaron Tward; Aldons J Lusis; Rhona M Jack; Lucio G Costa; Clement E Furlong
Journal:  Pharmacogenetics       Date:  2003-06
View more
  20 in total

Review 1.  Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.

Authors:  Daniel Seung Kim; Judit Marsillach; Clement E Furlong; Gail P Jarvik
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

Review 2.  Human PON1, a biomarker of risk of disease and exposure.

Authors:  C E Furlong; S M Suzuki; R C Stevens; J Marsillach; R J Richter; G P Jarvik; H Checkoway; A Samii; L G Costa; A Griffith; J W Roberts; D Yearout; C P Zabetian
Journal:  Chem Biol Interact       Date:  2010-03-23       Impact factor: 5.192

3.  Determinants of butyrylcholinesterase inhibition among agricultural pesticide handlers in Washington State: an update.

Authors:  Jennifer E Krenz; Jonathan N Hofmann; Theresa R Smith; Rad N Cunningham; Richard A Fenske; Christopher D Simpson; Matthew Keifer
Journal:  Ann Occup Hyg       Date:  2014-09-26

4.  Neurobehavioral assessment of mice following repeated postnatal exposure to chlorpyrifos-oxon.

Authors:  Toby B Cole; Jenna C Fisher; Thomas M Burbacher; Lucio G Costa; Clement E Furlong
Journal:  Neurotoxicol Teratol       Date:  2012-03-07       Impact factor: 3.763

5.  Repeated developmental exposure of mice to chlorpyrifos oxon is associated with paraoxonase 1 (PON1)-modulated effects on cerebellar gene expression.

Authors:  Toby B Cole; Richard P Beyer; Theo K Bammler; Sarah S Park; Federico M Farin; Lucio G Costa; Clement E Furlong
Journal:  Toxicol Sci       Date:  2011-06-14       Impact factor: 4.849

6.  Household organophosphorus pesticide use and Parkinson's disease.

Authors:  Shilpa Narayan; Zeyan Liew; Kimberly Paul; Pei-Chen Lee; Janet S Sinsheimer; Jeff M Bronstein; Beate Ritz
Journal:  Int J Epidemiol       Date:  2013-09-20       Impact factor: 7.196

Review 7.  Organophosphorus Compounds at 80: Some Old and New Issues.

Authors:  Lucio G Costa
Journal:  Toxicol Sci       Date:  2018-03-01       Impact factor: 4.849

Review 8.  Paraoxonase (PON1) polymorphisms Q192R and L55M are not associated with human longevity: A meta-analysis.

Authors:  Gan-Zhong Wei; Mei-Yan Zhu; Fang Wang; Yue-Guang Zhao; Shan-Shan Li; Tong-Yang Liu; Ying Luo; Wen-Ru Tang
Journal:  Z Gerontol Geriatr       Date:  2015-05-12       Impact factor: 1.281

9.  Human paraoxonase 1 hydrolysis of nanomolar chlorpyrifos-oxon concentrations is unaffected by phenotype or Q192R genotype.

Authors:  R Hunter Coombes; Edward C Meek; Mary Beth Dail; Howard W Chambers; Janice E Chambers
Journal:  Toxicol Lett       Date:  2014-08-02       Impact factor: 4.372

Review 10.  Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity.

Authors:  Lucio G Costa; Gennaro Giordano; Toby B Cole; Judit Marsillach; Clement E Furlong
Journal:  Toxicology       Date:  2012-07-31       Impact factor: 4.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.